Subgroup: nicotine patch; smoking cessation (≥ 6 month · people who smoke
It is very uncertain whether reduction and pharmacotherapy changes subgroup: nicotine patch; smoking cessation (≥ 6 month compared with reduction alone (very low certainty).
1 finding from 1 review
Smoking cessation · young people
It is very uncertain whether pharmacological interventions changes nicotine patch + bupropion vs nicotine patch + placebo Smoking… compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (control ‐ placebo) · young people
1 finding from 1 review
Intervention not reported
Cessation: Low‐nicotine cigarettes vs regular cigarettes · Smokers who cannot or do not want to quit smoking
It is very uncertain whether the intervention changes cessation: Low‐nicotine cigarettes vs regular cigarettes (very low certainty).
1 finding from 1 review
Intervention not reported
Number of smokers receiving nicotine gum/replacement therapy self‐report · Smokers treated by health professionals
The intervention showed no clear difference in number of smokers receiving nicotine gum/replacement therapy… (low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Cytisine may leads to higher smoking abstinence at longest compared with nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
It is very uncertain whether cytisine changes SAEs compared with nicotine replacement therapy (very low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiac SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with nicotine replacement therapy monotherapy (high certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline may leads to lower SAEs compared with nicotine replacement therapy monotherapy (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
1 finding from 1 review
Cardiac SAEs · people who smoke
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline showed no clear difference in smoking abstinence at longest compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline showed no clear difference in SAEs compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
Varenicline showed no clear difference in neuropsychiatric SAEs compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
Cardiac SAEs · people who smoke
Varenicline showed no clear difference in cardiac SAEs compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Combination leads to higher smoking cessation compared with single‐form nicotine replacement therapy (high certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).
3 findings from 1 review
RR 1.09 [0.93, 1.29]
5 studies · 1655 participants
Moderate
RR 1.19 [1, 1.41]
3 studies · 3446 participants
Moderate
RR 1.48 [1.06, 2.08]
1 study · 537 participants
Moderate
SAEs · people who smoke
Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).
2 findings from 1 review